Navigation Links
HealthCare Technologies Ltd. (NASDAQ: HCTL) Announces Receipt of NASDAQ Delisting Notice
Date:1/10/2008

NEW YORK, January 10 /PRNewswire-FirstCall/ -- HealthCare Technologies Ltd., (the "Company") today announced that it received a letter dated January 7, 2008 from the Staff of the Listing Qualifications Department (the "Staff Determination") of The NASDAQ Stock Market LLC, which indicated that because the Staff believes that the Company's Plan of Arrangement with NexGen Biofuels, Inc., which closed on December 31, 2007, constituted a reverse merger, the surviving entity is required to submit an initial listing application and satisfy Nasdaq's initial listing standards. On September 7, 2007, NexGen Biofuels, Ltd. submitted its listing application. However, the application was not approved because, among other things, the Company did not meet the minimum $4 bid price requirement for initial listing. Accordingly, the Company's securities will be delisted from The NASDAQ Stock Market. In that regard, unless the Company requests an appeal of this determination, NASDAQ will suspend trading of the Company's securities on the Capital Market at the opening of business on January 16, 2008.

In response, the Company intends to timely request a hearing before a NASDAQ Listing Qualifications Panel to address the Staff Determination and seek continued listing in accordance with applicable NASDAQ rules. The Company's hearing request will stay any delisting action pending the issuance of a decision by the Panel following the hearing.

In the event that the Company's appeal is unsuccessful, the Company believes that its ordinary shares will be eligible for trading on the OTC Bulletin Board, subject to the filing of a Form 211 by a market maker.

For more information on NexGen Biofuels, visit http://www.nexgenbiofuels.net

SAFE HARBOR: This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward looking statement made by or on behalf of HealthCare Technologies Ltd. Readers are referred to the documents filed by the company with the Securities and Exchange Commission, specifically the Form 8-K filed on January 7, 2008 that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

FOR: HealthCare Technologies Ltd.

CONTACT: Eran Rotem CFO

+972-3-9277232-3


'/>"/>
SOURCE HealthCare Technologies Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
2. Quest Diagnostics to Speak at the 26th Annual JPMorgan Healthcare Conference
3. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
4. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
5. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
6. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
8. ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008
9. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
10. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
11. AutoGenomics Invited to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and NEW YORK , ... Lumeon , a leading digital health company, ... a provider of telemedicine and remote patient monitoring, ... for telemedicine reimbursements.  DN Telehealth ... patients, in real-time, extending consultations beyond a physical ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of ...
(Date:2/23/2017)... SAN JOSE, Calif. , Feb. 23, 2017 ... an exclusive license for two key immunotherapy technologies ... The first technology provides a method to monitor ... therapy such as PD-L1 and CTLA-4.  The second ... detect if a patient is likely to have ...
(Date:2/23/2017)...  Seattle,s upscale Capitol Hill neighborhood, with its swanky shops, parks ... head lice treatment salon to set up shop. But there,s ... a French bistro on E Madison Ave, and CEO ... old lice clinic, we pride ourselves on being a destination ... of the stigma associated with lice. Everyone can get lice ...
Breaking Biology Technology:
(Date:2/3/2017)... , Feb. 3, 2017 A new ... Identity Strategy Partners, LLP (IdSP) . Designed to fill ... the complex identity market, founding partners Mark Crego ... 35 combined years just in identity expertise that span ... and non-profit leadership. The Crego-Kephart combined expertise has a ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... 24, 2017 Biopharm Reports has carried ... use of nuclear magnetic resonance spectroscopy (NMR). This ... profiled current practices, developments, trends and end-user plans ... growth and opportunities. These areas include growth in ... needs and innovation requirements, hyphenated NMR techniques, main ...
Breaking Biology News(10 mins):